Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering and Processing Services
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
GENEART AG has announces the signing of a framework agreement with the Swiss company Actelion Pharmaceuticals Ltd. Within the scope of this agreement, Actelion will receive system solutions for DNA engineering & processing exclusively from GENEART from now on.
Further contract terms were not disclosed. The contract does not restrict GENEART in supplying service solutions for other customers. The company, listed in the Swiss blue-chip index SMI®, is active in research, development and commercialization of biopharmaceutical therapies. The drugs developed and marketed by Actelion include Tracleer® for instance - an endothelin receptor antagonist for patients with pulmonary arterial hypertension.
"We are delighted that we have been able to convince another well-known company, Actelion, of the advantages of our technology for the development of biopharmaceutical therapeutics. Gene optimization and gene synthesis offer many advantages over conventional methods in molecular biology," Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.
He continued, "For instance, genes can be tailored to the respective customer project by our GeneOptimizer® software without any restrictions and subsequently produced within a few days. This not only shortens development times for biopharmaceuticals, but also increases the yield and thus reduces production and project costs. The fully DIN EN ISO 9001:2000 certified processes of GENEART and the world-wide highest production capacities additionally ensure reliable and quick processing of customer projects with observance of the required quality standards for the development of pharmaceutical agents."
Further contract terms were not disclosed. The contract does not restrict GENEART in supplying service solutions for other customers. The company, listed in the Swiss blue-chip index SMI®, is active in research, development and commercialization of biopharmaceutical therapies. The drugs developed and marketed by Actelion include Tracleer® for instance - an endothelin receptor antagonist for patients with pulmonary arterial hypertension.
"We are delighted that we have been able to convince another well-known company, Actelion, of the advantages of our technology for the development of biopharmaceutical therapeutics. Gene optimization and gene synthesis offer many advantages over conventional methods in molecular biology," Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.
He continued, "For instance, genes can be tailored to the respective customer project by our GeneOptimizer® software without any restrictions and subsequently produced within a few days. This not only shortens development times for biopharmaceuticals, but also increases the yield and thus reduces production and project costs. The fully DIN EN ISO 9001:2000 certified processes of GENEART and the world-wide highest production capacities additionally ensure reliable and quick processing of customer projects with observance of the required quality standards for the development of pharmaceutical agents."
